Terms: = Thyroid cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1
4 results:
1. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
2. A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-mkk4-p38 axis in triple negative breast cancer.
Wang L; Mi D; Hu J; Liu W; Zhang Y; Wang C; Chen Y; Chen C
Cancer Lett; 2023 Feb; 555():216049. PubMed ID: 36608865
[TBL] [Abstract] [Full Text] [Related]
3. microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
Sun Y; Zhang L; Zhang S
Cell Biochem Funct; 2020 Dec; 38(8):1017-1024. PubMed ID: 32495394
[TBL] [Abstract] [Full Text] [Related]
4. Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.
Aherne ST; Smyth P; Freeley M; Smith L; Spillane C; O'Leary J; Sheils O
Int J Mol Med; 2016 Aug; 38(2):433-45. PubMed ID: 27353001
[TBL] [Abstract] [Full Text] [Related]
